With an eye on both med tech and biopharmaceuticals, Orbimed Advisors LLC (New York) hauled in $950 million for its sixth fund. The cash is expected to support roughly 30 companies across all stages and sectors of the health care industry, with individual deals ranging from $10 million to $75 million.